Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25074150 | 1.00 | KDM6B (0.44) | KDM6BKDM4EMAPTCHRM4DGAT1 | |
| SCHEMBL23984151 | 0.81 | KDM6B (0.47) | KDM6BKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL25198223 | 0.79 | MEN1 (0.46) | KDM4EMAPTCHRM4DGAT1MEN1 | |
| SCHEMBL25191605 | 0.77 | POLB (0.41) | KDM4EMAPTDGAT1MEN1ALDH1A1 | |
| SCHEMBL462954 | 0.76 | PDE10A (0.51) | CHRM4PDE10A | |
| SCHEMBL31722492 | 0.76 | MAPT (0.46) | KDM6BKDM4EMAPTCHRM4MEN1 | |
| SCHEMBL24206622 | 0.76 | MAPT (0.46) | KDM6BKDM4EMAPTCHRM4MEN1 | |
| SCHEMBL14575465 | 0.76 | HRH3 (0.52) | MAPTDGAT1CYP3A4SOAT1ALDH1A1 | |
| SCHEMBL30804328 | 0.76 | HRH3 (0.52) | MAPTDGAT1CYP3A4SOAT1ALDH1A1 | |
| SCHEMBL25221491 | 0.76 | ALDH1A1 (0.39) | KDM6BKDM4EMAPTDGAT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | NURIX THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20240417402-A1 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES | GILEAD SCIENCES, INC. | 2024-12-19 | — | — | US | disclosed |
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-4367118-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | Nurix Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117813307-A | Difunctional degradants of interleukin-1 receptor related kinase and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023023255-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | IRAK1, IRAK2, IRAK4 | KDM6B 1893/4885KDM4E 1263/4885MAPT 900/4885 |
| US-20240417402-A1 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES | IRAK1, IRAK2, IRAK4 | KDM6B 711/4885KDM4E 689/4885MAPT 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.